Elite Pharmaceuticals, Inc. (ELTP)

Elite Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Net Income	20.11	20.11	4,410	8.9	5.09	-2.24
Depreciation & Amortization	1.53	1.53	1.34	1.43	1.52	1.51
Share-Based Compensation	8.51	8.51	0.58	0.78	0.94	1.03
Other Operating Activities	-33.45	-33.44	-4,408.49	-4.61	-4.35	-2.09
Operating Cash Flow	-3.29	-3.28	3.34	6.51	3.19	-1.79
Operating Cash Flow Growth	-	-	-48.70%	103.78%	-	-
Capital Expenditures	-0.81	-0.81	-5.74	-0.5	-0.33	-0.03
Acquisitions	0	0	0	0	0.07	0
Investing Cash Flow	-0.81	-0.81	-5.74	-0.5	-0.26	-0.03
Common Stock Issued	0	159.92	39.33	14.35	0.04	1.44
Other Financing Activities	3.4	-156.54	-37.62	-15.02	-0.91	-0.75
Financing Cash Flow	3.4	3.39	1.7	-0.67	-0.87	0.69
Net Cash Flow	-0.72	-0.73	-0.7	5.34	2.06	-1.14
Free Cash Flow	-4.1	-4.09	-2.4	6.01	2.86	-1.83
Free Cash Flow Growth	-	-	-	109.85%	-	-
Free Cash Flow Margin	-7.25%	-7.23%	-0.01%	18.63%	11.28%	-10.16%
Free Cash Flow Per Share	-0.00	-0.00	-0.00	0.01	0.00	-0.00

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.